REMO HOLANDA DE MENDONCA FURTADO

(Fonte: Lattes)
Índice h a partir de 2011
15
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico

Resultados de Busca

Agora exibindo 1 - 10 de 12
  • article 3 Citação(ões) na Scopus
    Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial
    (2019) NICOLAU, Jose C.; STEVENS, Susanna R.; AL-KHALIDI, Hussein R.; JATENE, Fabio B.; FURTADO, Remo H. M.; DALLAN, Luis A. O.; LISBOA, Luiz A. F.; DESVIGNE-NICKENS, Patrice; HADDAD, Haissam; JOLICOEUR, E. Marc; PETRIE, Mark C.; DOENST, Torsten; MICHLER, Robert E.; OHMAN, E. Magnus; MADDURY, Jyotsna; ALI, Imtiaz; DEJA, Marek A.; ROULEAU, Jean L.; VELAZQUEZ, Eric J.; HILL, James A.
    Background: The STICH trial showed superiority of coronary artery bypass plus medical treatment (CABG) over medical treatment alone (MED) in patients with left ventricular ejection fraction (LVEF) <= 35%. In previous publications, percutaneous coronary intervention (PCI) prior to CABG was associated with worse prognosis. Objectives: The main purpose of this study was to analyse if prior PCI influenced outcomes in STICH. Methods and results: Patients in the STICH trial (n=1212), followed for a median time of 9.8 years, were included in the present analyses. In the total population, 156 had a prior PCI (74 and 82, respectively, in the MED and CABG groups). In those with vs. without prior PCI, the adjusted hazard-ratios (aHRs) were 0.92 (95% CI=0.74-1.15) for all-cause mortality, 0.85 (95% CI=0.64-1.11) for CV mortality, and 1.43 (95% CI=1.15-1.77) for CV hospitalization. In the group randomized to CABG without prior PCI, the aHRs were 0.82 (95% CI=0.70-0.95) for all-cause mortality, 0.75 (95% CI=0.62-0.90) for CV mortality and 0.67 (95% CI=0.56-0.80) for CV hospitalization. In the group randomized to CABG with prior PCI, the aHRs were 0.76 (95% CI=0.50-1.15) for all-cause mortality, 0.81 (95% CI=0.49-1.36) for CV mortality and 0.61 (95% CI=0.41-0.90) for CV hospitalization. There was no evidence of interaction between randomized treatment and prior PCI for any endpoint (all adjusted p > 0.05). Conclusion: In the STICH trial, prior PCI did not affect the outcomes of patients whether they were treated medically or surgically, and the superiority of CABG over MED remained unchanged regardless of prior PCI.
  • conferenceObject
    EFFECT OF TICAGRELOR AND CLOPIDOGREL ON CORONARY MICROCIRCULATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
    (2019) SCANAVINI FILHO, Marco Antonio; BERWANGER, Otavio; MATHIAS JUNIOR, Wilson; AGUIAR, Miguel Osman; CHIANG, Hsu Po; BARACIOLI, Luciano Moreira; LIMA, Felipe Gallego; MENEZES, Fernando Reis; DALCOQUIO, Talia; FURTADO, Remo Holanda M.; LUCA, Fabio Augusto De; UEZATO, Delcio; RAMIRES, Jose Antonio Franchini; KALIL FILHO, Roberto; NICOLAU, Jose Carlos
  • article 3 Citação(ões) na Scopus
    Platelet function, coagulation and fibrinolysis in patients with previous coronary and cerebrovascular ischemic events
    (2019) BARBOSA, Carlos Jose Dornas Goncalves; BARREIROS, Renata de Souza; FRANCI, Andre; ARANTES, Flavia Bittar Brito; FURTADO, Remo Holanda de Mendonca; STRUNZ, Celia Maria Cassaro; ROCHA, Tania Rubia Flores da; BARACIOLI, Luciano Moreira; RAMIRES, Jose Antonio Franchini; KALIL-FILHO, Roberto; NICOLAU, Jose Carlos
    OBJECTIVES: Ischemic stroke (IS) or transient ischemic attack (TIA) history is present in 4-17% of patients with coronary artery disease (CAD). This subgroup of patients is at high risk for both ischemic and bleeding events. The aim of this study was to determine the role of platelet aggregability, coagulation and endogenous fibrinolysis in patients with CAD and previous IS or TIA. METHODS: A prospective case-control study that included 140 stable CAD patients divided into two groups: the CASE group (those with a previous IS/TIA, n=70) and the CONTROL group (those without a previous IS/TIA, n=70). Platelet aggregability (VerifyNow Aspirin (R) and VerifyNow P2Y12 (R)), coagulation (fibrinogen and thromboelastography by Reorox (R)) and endogenous fibrinolysis (D dimer and plasminogen activator inhibitor-1) were evaluated. RESULTS: Patients in the CASE group presented significantly higher systolic blood pressure levels (135.84 +/- 16.09 vs 123.68 +/- 16.11, p <0.01), significantly more previous CABG (25.71% vs 10%, p=0.015) and significantly higher calcium channel blocker usage (42.86% vs 24.29%, p=0.02) than those in the control group. In the adjusted models, low triglyceride values, low hemoglobin values and higher systolic blood pressure were significantly associated with previous IS/TIA (CASE group). Most importantly, platelet aggregability, coagulation and fibrinolysis tests were not independently associated with previous cerebrovascular ischemic events (CASE group). CONCLUSION: Platelet aggregability, coagulation and endogenous fibrinolysis showed similar results among CAD patients with and without previous IS/TIA. Therefore, it remains necessary to identify other targets to explain the higher bleeding risk presented by these patients.
  • conferenceObject
    Effect of exercise stress test on platelet function in patients with recent acute myocardial infarction
    (2019) DALCOQUIO, T.; SANTOS, M. A.; ALVES, L. S.; ARANTES, F. B. B.; FERREIRA-SANTOS, L.; RONDON, M. U. P. B.; ALVES, M. J. N. N.; FURTADO, R. H. M.; FERRARI, A. G.; GENESTRETI, P. R.; REALI, F. R.; RODRIGUEZ, M. R. S.; FRANCI, A.; NEGRAO, C. E.; NICOLAU, J. C.
  • conferenceObject
    Platelet aggregability evaluation in patients with acute coronary syndromes scheduled for coronary artery bypass graft. The PLAT-CABG study
    (2019) NAKASHIMA, C. A. K.; DALLAN, L. A. O.; LISBOA, L. A. F.; HAJJAR, L. A.; SOEIRO, A. M.; SILVA, B. A.; COSTA, M. S. S.; DORNAS, C. J. C. B.; DALCOQUIO, T. F.; FURTADO, R. H. M.; BARACIOLI, L. M.; FUKUSHIMA, J. T.; GURBEL, P. A.; GIUGLIANO, R. P.; NICOLAU, J. C.
  • conferenceObject
    Adenosine Plasmatic Concentration in Coronary Artery Disease Patients With and Without Chronic Kidney Disease
    (2019) FRANCI, Andre; BARBOSA, Carlos; DALCOQUIO, Talia; SALSOSO, Rocio; FURTADO, Remo H.; STRUNZ, Celia; GENESTRETI, Paulo; LIMA, Viviane; SCANAVINI, Marco; FERRARI, Aline G.; BARACIOLI, Luciano; NICOLAU, Jose C.
  • conferenceObject
    INCREASED BODYWEIGHT AND INADEQUATE RESPONSE TO ASPIRIN IN INDIVIDUALS WITH CORONARY ARTERY DISEASE
    (2019) FURTADO, Remo Holanda de Mendonca; ARANTES, Flavia; BARBOSA, Carlos; FRANCI, Andre; MENEZES, Fernando; SALSOSO, Rocio; DALCOQUIO, Talia; NAKASHIMA, Carlos; SCANAVINI FILHO, Marco; FERRARI, Aline; GENESTRETI, Paulo; BARACIOLI, Luciano; NICOLAU, Jose C.
  • conferenceObject
    Impact of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes and Reduced Left Ventricular Ejection Fraction
    (2019) SALSOSO, Rocio; GENESTRETI, Paulo; FRANCI, Andre; DALCOQUIO, Talia; NAKASHIMA, Carlos A.; SCANAVINI, Marco; FERRARI, Aline G.; FURTADO, Remo H.; LIMA, Felipe G.; GIRALDEZ, Roberto R.; BARACIOLI, Luciano; NICOLAU, Jose C.
  • article 6 Citação(ões) na Scopus
    Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease
    (2019) FURTADO, Remo H. M.; GIUGLIANO, Robert P.; DALCOQUIO, Talia F.; ARANTES, Flavia B. B.; BARBOSA, Carlos J. D. G.; GENESTRETI, Paulo R. R.; FRANCI, Andre; MENEZES, Fernando R.; NAKASHIMA, Carlos A. K.; SCANAVINI FILHO, Marco A.; FERRARI, Aline G.; SALSOSO, Rocio; BARACIOLI, Luciano M.; NICOLAU, Jose C.
    Recent reports have suggested that aspirin effect might be influenced by bodyweight, with decreased efficacy in heavier individuals. We investigated the influence of bodyweight on aspirin pharmacodynamics in two independent datasets of patients taking non-enteric coated aspirin 100mg QD for coronary artery disease (CAD). In the first dataset, 368 patients had their platelet aggregation assessed using VerifyNow Aspirin and measured in Aspirin Reaction Units (ARU). In the second dataset, 70 patients had serum thromboxane B2 (TXB2) dosage assessed by an ELISA assay and measured in pg/mL. Platelet aggregation was independently associated with bodyweight, with 8.41 (95% CI 1.86-14.97; adjusted p-value=0.012) increase in ARU for every 10kg. Furthermore, the rate of non-response to aspirin (defined as ARU550) was significantly associated with increased bodyweight (adjusted p-value=0.007), with OR=1.23 (95% CI 1.06-1.42) for every 10kg. Similar results were found considering body mass index (in kg/m(2)), with 15.5 (95% CI 5.0 to 25.9; adjusted p-value=0.004) increase in ARU for every 10kg and non-response OR=1.43 (95% CI 1.13 to 1.81, adjusted p-value=0.003) for every 5kg/m(2). Moreover, serum TXB2 was higher in patients weighting more than 70kg (222.6 +/- 62.9 versus 194.9 +/- 61.9pg/mL; adjusted p-value=0.018). In two different datasets of patients with CAD on non-enteric coated aspirin 100mg QD, increased bodyweight was independently associated with impaired response to aspirin.
  • article 1 Citação(ões) na Scopus
    Cardiology Training in Brazil and Developed Countries: Some Ideas for Improvement
    (2019) GODOY, Lucas Colombo; FARKOUH, Michael E.; MANTA, Isabela C. K. Abud; DALCOQUIO, Ialia F.; FURTADO, Remo Holanda de Mendonca; YU, Eric H. C.; GUN, Carlos; NICOLAU, Jose Carlos
    Huge variations exist in cardiology training programs across the world. In developing (middle-income) countries, such as Brazil, to find the right balance between training improvements and social and economic conditions of the country may be a difficult task. Adding more training years or different mandatory rotations, for instance, may be costly and not have an immediate direct impact on enhancing patient care or public health. In this text, we compare the Brazilian cardiology training system with other proposals implemented in developed countries from North America and Europe, aiming to point out issues worth of future discussion. Factors such as training rotations and competencies, and program duration and distribution across the countries are presented. The number of first year cardiology trainees per inhabitants is similar between Brazil and the United States (0.24 medical residents/100,000 inhabitants in Brazil and 0.26 medical residents/100,000 inhabitants in the USA). These numbers should be analyzed considering the inequality in training program distribution across Brazil, since most centers are located in the Southeast and South regions. Having more residency programs in distant areas could improve cardiovascular care in these areas. Duration of cardiology Residency Training is shorter in Brazil (two years) in comparison with developed countries (> 3 years). Brazilian residency programs give less emphasis to scientific research and diagnostic methods. Unifying minimum training requirements across the globe would facilitate the development of international learning opportunities and even professional exchange around the world.